IDENTIFICATION OF GENETIC VARIANTS ASSOCIATED WITH RESPONSE TO METHOTREXATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE OPTIMA STUDY

A. Skapenko1, H. Schulze-Koops1, V. Devanarayan2, K. Idler3, F. Hong2, J.S. Smolen4, A. Kavanaugh5, H. Kupper6, J. Waring3.

1Div. of Rheumatology, Univ. of Munich, Munich, Germany; 2AbbVie Bioresearch Center, Worcester, MA; 3AbbVie Inc, North Chicago, IL, United States; 4Medical University of Vienna & Heitzing, Vienna, Austria; 5UCSD, San Diego, CA, United States; 6AbbVie Deutschland GmbH and Co. KG., Ludwigshafen, Germany

Background: Genetic factors related to treatment response in rheumatoid arthritis (RA) have been described. International recommendations for the management of RA suggest initial therapy with synthetic DMARDs, with methotrexate (MTX) typically administered as first-line therapy. However, responses to MTX are
variable, and more than 30% of patients fail to respond. Despite many studies, few genetic factors specifically associated with MTX response have been identified.

**Objectives**: To identify genetic variants associated with response to MTX in patients with early RA.

**Methods**: OPTIMA was a 78-week, multicenter, randomized, double-period, double-blind study in which patients were randomized 1:1 to combination therapy with adalimumab plus MTX or MTX alone during the initial study period (26 weeks). Enrolled patients were invited to participate in a genetic sub-study and asked to provide written, informed consent. 384 variants in genes previously shown to be associated with RA or treatment response were assayed using the Illumina BeadXpress GoldenGate Assay. Changes in the 28-joint disease activity score (DAS28) and the total Sharp score (TSS) following 26 weeks of treatment were assessed for association with allele status using genotypic tests.

**Results**: A total of 448 patients randomized to MTX were included in the genetic sub-study. Two SNPs in MTHFR (rs1801133 and rs1801131) and one SNP in ATIC (rs2372536), previously shown to be associated with MTX response, were not associated with a change in DAS28 or TSS following MTX treatment. However, other SNPs within genes that have been associated with RA or treatment response, such as ABCB1, TNF-alpha, PTPRC, STAT4 and HLA-DRB1, did show association with MTX treatment (Table). For some genes, such as ABCB1, multiple SNPs were identified, suggesting that haplotype analysis could identify stronger associations. SNPs within ABCB1 and PTPRC were also associated with a change in TSS. In addition, a SNP within ADORA2a associated with a change in TSS. SNPs within this gene have previously been associated with MTX toxicity, however, analysis of the impact of this gene on efficacy have been more limited.

**Gene** | **SNP** | **Mean change in DAS28** (major allele, # subjects) | **Mean change in DAS28** (heterozygote, # subjects) | **Mean change in DAS28** (minor allele, # subjects) | **Mean change in DAS28** (p-value) | **Mean change in TSS** (p-value) |
--- | --- | --- | --- | --- | --- | --- |
ABCB1 | rs1202184 | −2.3 (87) | −1.8 (196) | −2.2 (82) | 0.0071 | NS |
ABCB1 | rs2188526 | −2.2 (104) | −1.8 (187) | −2.3 (76) | 0.0039 | NS |
ABCB1 | rs4148738 | −2.2 (109) | −1.8 (193) | −2.3 (66) | 0.011 | NS |
ABCB1 | rs4148743 | −2.2 (83) | −1.8 (202) | −2.2 (83) | 0.018 | 0.033 |
PTPRC | rs2369952 | −1.8 (150) | −2.2 (147) | −2.1 (38) | 0.033 | 0.029 |
STAT4 | rs11685878 | −1.8 (142) | −2.2 (153) | −2.0 (70) | 0.035 | NS |
STAT4 | rs1227969 | −1.9 (217) | −2.3 (128) | −1.8 (23) | 0.025 | NS |
HLA-DRB1 | rs4678 | −2.0 (243) | −2.0 (118) | −3.4 (8) | 0.016 | NS |

**Conclusions**: Genetic polymorphisms in genes such as ABCB1, TNF-alpha, PTPRC, STAT4 and HLA-DRB1 were shown to associate with MTX treatment in the OPTIMA study. These results may prove useful for the development of future diagnostic tests or personalized therapeutics for MTX treatment.

**References**:

**Acknowledgements**: AbbVie sponsored the study (NCT00420927), contributed to its design, and participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final version. Medical writing support was provided by Laurel M. Farmer, PhD, of AbbVie Inc.


**DOI**: 10.1136/annrheumdis-2014-eular.1318